Analysts Set LifeStance Health Group, Inc. (NASDAQ:LFST) Target Price at $8.60

LifeStance Health Group, Inc. (NASDAQ:LFST) has received a consensus recommendation of “Hold” from the six research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.83.

LFST has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price target on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Monday, March 4th. Barclays upped their price target on LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Thursday, February 29th. Morgan Stanley reaffirmed an “overweight” rating and issued a $10.00 price target on shares of LifeStance Health Group in a research note on Monday, April 22nd. Finally, Jefferies Financial Group increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $6.20 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.11 and a quick ratio of 1.11. The stock has a market cap of $2.37 billion, a PE ratio of -12.16 and a beta of 1.34. The stock has a 50-day moving average of $6.44 and a 200-day moving average of $6.53. LifeStance Health Group has a one year low of $4.74 and a one year high of $9.59.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The company had revenue of $280.60 million during the quarter, compared to the consensus estimate of $263.14 million. LifeStance Health Group had a negative net margin of 17.64% and a negative return on equity of 12.66%. As a group, sell-side analysts expect that LifeStance Health Group will post -0.3 earnings per share for the current year.

Insider Buying and Selling

In other LifeStance Health Group news, insider Danish J. Qureshi sold 12,965 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the transaction, the insider now owns 4,911,050 shares of the company’s stock, valued at approximately $29,122,526.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other LifeStance Health Group news, insider Kevin Michael Mullins sold 44,540 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $6.33, for a total transaction of $281,938.20. Following the completion of the transaction, the insider now owns 4,745,352 shares of the company’s stock, valued at approximately $30,038,078.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Danish J. Qureshi sold 12,965 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $5.93, for a total value of $76,882.45. Following the transaction, the insider now directly owns 4,911,050 shares of the company’s stock, valued at approximately $29,122,526.50. The disclosure for this sale can be found here. In the last three months, insiders sold 245,463 shares of company stock valued at $1,786,868. 8.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LifeStance Health Group

A number of large investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of LifeStance Health Group by 6.7% in the 3rd quarter. FMR LLC now owns 28,178,666 shares of the company’s stock valued at $193,587,000 after buying an additional 1,758,427 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of LifeStance Health Group by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 7,525,195 shares of the company’s stock valued at $51,698,000 after buying an additional 84,373 shares during the last quarter. Brown Advisory Inc. boosted its holdings in shares of LifeStance Health Group by 25.9% in the 4th quarter. Brown Advisory Inc. now owns 5,158,980 shares of the company’s stock valued at $40,395,000 after buying an additional 1,062,887 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of LifeStance Health Group by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 4,006,344 shares of the company’s stock valued at $31,370,000 after buying an additional 110,457 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in shares of LifeStance Health Group by 26.6% in the 3rd quarter. Rock Springs Capital Management LP now owns 3,670,000 shares of the company’s stock valued at $25,213,000 after buying an additional 770,000 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.